Skip to main content
PMC home page
Cancer Medicine logoLink to Cancer Medicine
. 2019 May 1;8(7):3491–3501. doi: 10.1002/cam4.2213

IL‐25 promotes cisplatin resistance of lung cancer cells by activating NF‐κB signaling pathway to increase of major vault protein

Weiming Shen 1,2, Yang Qiu 1, Jingyao Li 1, Chao Wu 1,2, Zhihui Liu 2,3, Xiaorong Zhang 4, Xiaohong Hu 4, Yi Liao 1,✉, Haidong Wang 1,✉
PMCID: PMC6601590  PMID: 31044552

Abstract

As an inflammatory factor, IL‐25 has been studied in variouscancers, but it is rarely reported in cancer chemotherapy resistance. Major vault protein (MVP), as a gene associated with lung multidrug resistance, is associated with multiple chemotherapy resistances of lung cancer. However, the relationship between IL‐25 and MVP in lung cancer cells has not been studied. In this study, we found that both IL‐25 and MVP were elevated expressed in cisplatin‐resistant lung adenocarcinoma cell line (A549/CDDP). Silencing of IL‐25 resulted in down‐regulation of MVP expression and reduced cisplatin tolerance of A549/CDDP cells. Overexpression of IL‐25 resulted in increase of MVP expression and the cisplatin tolerance in A549 cells. In addition, we found that the extracellular IL‐25 could stimulate the expression of MVP and activate the NF‐κB signaling pathway. Further, animal models also confirmed that IL‐25 reduced the sensitivity of xenografts to chemotherapy. Taken together, we believe that the up‐regulation of IL‐25 induces MVP expression contributing to chemotherapy resistances of lung cancer cells. Our findings suggest that interference the expression of IL‐25 might be potential treatment strategies for the clinical reversing the chemotherapy resistance.

Keywords: chemotherapy, cisplatin resistance, IL‐25, lung cancer, MVP

1. INTRODUCTION

Lung cancer, especially the nonsmall‐cell lung cancer (NSCLC), is the leading cause of malignant carcinoma‐related deaths.1, 2 Platinum‐based drugs are currently the first line of chemotherapy for NSCLC, while patients are easily tolerated and tumors are further developed. However, the underlying mechanisms of Platinum‐based drug resistance remain largely unclear.3, 4, 5, 6

IL‐25, also called IL‐17E, is a member of IL‐17 family.7, 8 IL‐25 has a similar structure with IL‐17A, however, its biological function is different from IL‐17A or other IL‐17 family cytokines, such as IL‐17B and IL‐17F.9 As the most well‐characterized cytokines in this family, IL‐17A and IL‐17F can induce the recruitment of neutrophils and protect against extracellular pathogens.9, 10, 11 In addition, IL‐17A plays an important role in the development of several autoimmune diseases.10 As to IL‐25, it stimulates the production of T helper 2‐type cytokines.11 Recent studies have demonstrated that IL‐25 functions as an antitumor factor suppressing tumor growth in several xenograft tumor models, such as melanoma, breast, lung, colon, and pancreatic cancers.12, 13, 14 Contrarily, some studies have also reported IL‐25 may have a tumor promoting effect. For example, increased expression of IL‐17RB (IL‐25 receptor) was strongly correlated with poor prognosis in breast cancer patients, and blocking IL‐17B‐IL‐17RB signaling with an anti‐IL‐17RB antibody resulted in reducing metastasis in pancreatic cancer by silencing NF‐κB‐mediated multiple chemokines release.15, 16 Therefore, the different functions of IL‐25 in different cells remain to be further revealed.

Major vault protein (MVP), also known as LRP (lung resistance‐related protein), is constitutively expressed in human tissues which participates in the composition of vault particles and nuclear pore complex.17, 18, 19, 20, 21 Major vault protein (MVP) plays an important role in transporting small molecules from the nucleus to the cytoplasm.22, 23 Therefore, it is involved in physiological metabolism, self‐protection, anti‐apoptosis, and anti‐infection.24, 25 Studies have demonstrated that LRP was prevalently expressed in a large set of cancer cell lines which have not been subjected to drug selection, and expressed in certain highly drug‐resistant cell lines without expression of MDRI/Pgp.26, 27, 28 In addition, studies have suggested that increased level of MVP expression indicating a poor response to chemotherapy in many cancers.29, 30, 31 Taken together, these results suggested that multidrug resistance mechanism associated with MVP expression may be widespread in human malignancies. However, the precise molecular mechanism of MVP regulation is largely unknown.

In the present study, we occasionally found that IL‐25 and MVP expressions both increased in cisplatin‐resistant lung cancer cells (A549/CDDP). To further elucidate the relationship of IL‐25 and MVP in drug‐resistant lung cancer cells, we first explored the effect of IL‐25 on A549 and A549/CDDP cells responding to cisplatin treatment. Then, we studied the regulation of IL‐25 on MVP expression in these cells and explored its possible regulatory mechanisms. Finally, in vivo experiments were performed to verify the effect of IL‐25 on chemotherapy response. Our findings elucidated a novel mechanism of IL‐25‐MVP cascade regulated formation of cisplatin resistance.

2. MATERIALS AND METHODS

2.1. Cell culture and cell lines

Human lung adenocarcinoma A549 cells were cultured in RPMI 1640 medium (SH30809.01, Hyclone, America) containing 10% fetal bovine serum (SV30087.03, Hyclone, America) and 100 μg/mL penicillin/streptomycin (C0222; Beyotim Biotechnology, China) at 37°C with 5% CO2. The cisplatin‐resistant A549 cell line (A549/CDDP) was established by treating A549 with gradient increased cisplatin (CDDP, 0.5‐6 μg/mL) for 3 months. Cisplatin (479306‐1G, Sigma‐Aldrich, America) is dissolved with physiological saline solution and protected from light at −20°C.

2.2. Cell viability assay and half maximal inhibitory concentration (IC50) measurement

Cells were seeded into 96‐well plates (5 × 103 cells/well) and cultured overnight. Then, indicated concentration of CDDP was added to the experimental and control groups, respectively. After incubation for 24 hours, cell counting Kit‐8 reagent (LH650, Dojindo, Japan) was added to each well and incubated at 37°C for 1 hour. The absorbance of each well was measured at 450 nm using a Microplate Reader. The half maximal inhibitory concentration (IC50) was measured by linear regression.

2.3. Transwell invasion assay

2×105 cells were added into the upper chamber which was precoated with Matrigel (ECM gel, 3422, COSTAR, USA), and cultured in medium without serum. The medium containing 5% fetal bovine serum in the lower chamber served as chemoattractant. After 24 hours of incubation, cells were fixed by precooled methanol for 30 minutes and stained with 0.2% crystal violet solution for 30 minutes. The cells that did not invade through the pores were carefully wiped out with cotton wool. Invasive cells adhering to the undersurface of the filter were counted using an inverted microscope.

2.4. ELISA assay

2 × 106 cells were seeded in each well of 6‐well plate and allowed to incubate in CO2 incubator at 37°C. Supernatants were collected after 24 hours of incubation. ELISA assay for cytokines IL‐25 was performed using human cytokine ELISA Kit (SEB694Hu, Cloud‐Clone Corp, China) according to manufacturer instructions.

2.5. Western blot analysis

Cells in 6‐well plate were allowed to grow to 80% density. For harvesting the protein, cells were washed twice with PBS and lysed with 100 μL ice cold 1× RIPA lysis buffer. For each sample, a total of 50 μg protein was conducted electrophoresis in SDS‐PAGE gel at 100 V for 100 minutes and then transferred to PVDF membrane at 200 mA for 120 minutes by ice‐bath. The membrane was incubated with antibodies of IL‐25 (NBP2‐48858, Novus, USA), MVP (EPR13227(B), Abcam, USA), IκBα (L35A5, CST, USA), phospho‐IκBα (Ser32/36, 5A5, CST, USA), phospho‐NF‐κB p65 (Ser536, E1Z1T, CST, USA), NF‐κB (L8F6, CST, USA) and GAPDH (60004‐1‐Ig, Proteintech, China). ECL kit was used to visualize and analyze the expression of indicated proteins.

2.6. siRNA transfection

All small interfering RNAs (siRNAs) used in this study were synthesized by GenePharma (Shanghai, China). HiPerFect Transfection Reagent (Qiagen, Germany) was used to transfect siRNA to A549/CDDP according to manufacturer instructions.

siRNA sequences were listed as follow:

  • si‐IL‐25‐#1: 5’‐GGAGAUAUGAGUUGGACAGTT‐3’;

  • si‐IL‐25‐#2: 5’‐CUGUCCAACUCAUAUCUCCTT‐3’;

  • Negative control siRNA‐1#: 5’‐UUCUCCGAACGUGUCACGUTT‐3’;

  • Negative control siRNA‐2#: 5’‐ACGUGACACGUUCGGAGAATT‐3’.

2.7. IL‐25 overexpression

IL‐25 coding DNA was amplified from human cDNA library and then sub‐cloned into pCMV3‐C‐GFPSpark plasmid (Sino Biological, China). Empty or IL‐25‐containing plasmid were transfected into A549 cells by using Effectene® Transfection Reagent (Qiagen, Germany) according to manufacturer instructions.

2.8. Immunohistochemistry

The streptavidin‐biotin peroxidase complex method was performed for immunohistochemical staining of formalin‐fixed, paraffin embedded tissue sections. Indicated first antibody (1:200) was added for 1 hour at 37°C and 4°C overnight. Sections were permanently developed by using diaminobenzidine (Solarbio, China).

2.9. Establishment of xenografts and CDDP treatment

Four‐week‐old female BALB/c nude mice were purchased from the animal center of Army Medical University (Chongqing, China). For in vivo chemosensitivity assays, A549 cells were subcutaneously inoculated into nude mice (8 mice per group, 1 × 106 cells for each mouse). Tumor growth was examined every other day, and tumor volumes were calculated using the equation V = 0.52 × A × B2 (mm3), A represented the largest diameter and B represented the perpendicular diameter. When the average tumor size reached 500 mm3, CDDP was administered by subcutaneous injection at a dose of 5 mg/kg once every 2 days for 3 times in total. The tumor volumes were measured every 2 days for 2 weeks since the last CDDP treatment. Then all mice were sacrificed to harvest the tumor tissues to perform immunohistochemistry assay and hematoxylin & eosin staining. All procedures involving animal were approved by the Committee on the Use and Care on Animals (Army Medical University, Chongqing, China). All animals received humane care according to the criteria outlined in the “Guide for the Care and Use of Laboratory Animals” prepared by the National Academy.

2.10. Cytoskeletal staining

Cells (2 × 104) were planted on the carry sheet glass (48‐well size) and allowed to grow to 60% density. Then cells were fixed by 4% paraformaldehyde for 30 minutes. Phalloidine (1:500 diluted, A12379, Thermo Fisher, USA) was used to stain the fixed cells for 1 hour in absence of light. DAPI (C0065, Solarbio, China) was used to stain the nucleus.

2.11. Cell apoptosis analysis

After trypsin, cells were collected by centrifuge for 5 minutes at 1000 g and washed twice with PBS. Then for each sample, 1 × 105 cells were separated and resuspended into 0.5 mL PBS for apoptosis staining according to manufacturer instructions (C1063, Beyotime, China). Flow cytometry was performed immediately to analyze the apoptosis ratio.

2.12. Statistical analysis

Statistical analyses were performed using SPSS.23 software. All data from 3 independent experiments were expressed as mean ± SD. Differences were assessed by two‐tailed Student's t test. P < 0.01 was considered statistically significant.

3. RESULTS

3.1. The generation of a cisplatin‐resistant lung cancer cell line

To better understand the biological mechanisms of chemotherapy resistance in lung cancer cells and reveal the possible reversion opportunities, we generated a cisplatin‐resistant lung cancer cell line (A549/CDDP) by inducing A549 cells with increasing concentration of cisplatin (from 0.5 to 6.0 μg/mL) for 3 months. A549/CDDP cells showed spindle shape and were relatively dispersed (Figure 1A,B). CCK8 cell viability assay results showed that A549/CDDP cells exhibited a stronger cisplatin tolerance (Figure 1C) with the IC50 of cisplatin increased 2.15‐folds (Figure 1D), compared to that in parental A549 control cells. Additionally, the invasion ability significantly increased in A549/CDDP cells (Figure 1E), along with the reducing of E‐cadherin and increasing of mmp9 expression (Figure S1A). These data suggested that we have generated a cisplatin‐resistant cell line A549/CDDP.

Figure 1.

Figure 1

Open in a new tab

The establishment of a cisplatin‐resistant lung cancer cell line. A, The morphology of parental A549 cells and A549/CDDP cells (magnification, ×100). B, Phalloidine stain the cytoskeleton of parental A549 cells and A549/CDDP cells (magnification, ×200). C, The inhibition ratio of cells treated with different concentration of CDDP and (D) the IC50 value of these cells; *P < 0.01 vs A549 cells. Data are means ± SD from three independent experiments. E, The invasion ability of A549 and A549/CDDP cells; *P < 0.01 vs A549 cells. Data are means ± SD from three independent experiments

3.2. IL‐25 is associated with cisplatin resistance of lung cancer cells

In order to investigate whether IL‐25 expression might be involved in the formation of cisplatin resistance in A549 cells, we first detected the IL‐25 expression by western blotting assay in A549 and A549/CDDP cells. Our data showed that, compared to A549 cells, A549/CDDP cells enhanced the expression of IL‐25 (Figure 2A). Then, we successfully overexpressed IL‐25 in A549 cells and silenced IL‐25 expression in A549/CDDP cells by transfecting the overexpression plasmid or knockdown siRNA, respectively (Figure 2B,C). To further investigate whether alteration of IL‐25 expression might affect the cisplatin resistance in A549 cells, CCK‐8 assay was used to study the effect of IL‐25 expression on the cisplatin tolerance in these cells. Our results indicated that IL‐25 overexpressed A549 cells showed greater resistant abilities to the cisplatin treatment, compared to that in A549 cells and A549 cells transfected with pCMV3 control plasmid (Figure 2D). Whereas, IL‐25 silenced A549/CDDP cells exhibited frailer resistant abilities to the cisplatin treatment, compared to that in A549/CDDP cells and A549/CDDP cells transfected with NS control siRNA (Figure 2E). These data suggested that IL‐25 is involved in cisplatin resistance in lung cancer cells.

Figure 2.

Figure 2

Open in a new tab

The expression of IL‐25 affects the cisplatin resistance of lung cancer cells. A, The expression of IL‐25 in A549 and A549/CDDP cells. B, IL‐25 overexpressed in A549 cells. C, silence of IL‐25 expression by siRNA in A549/CDDP cells. D, IL‐25 overexpression desensitizes A549 cells to cisplatin treatment. E, Silence of IL‐25 expression sensitizes A549/CDDP cells to cisplatin treatment. *P < 0.01 vs indicated controls, all figures represent the average of three sets of independent experiments

3.3. Extracellular secreted IL‐25 desensitizes lung cancer cells to cisplatin treatment

Given that IL‐25 is a cytokine which can be secreted into extracellular matrix, we detected the extracellular IL‐25 protein level by ELISA in A549 and A549/CDDP cells. Our data showed that, compared to A549 cells, A549/CDDP cells enhanced the secretion of IL‐25 (Figure 3A). Additionally, we found that overexpression of IL‐25 in A549 cells also increased its secretion (Figure 3B), while silencing of IL‐25 in A549/CDDP cells decreased its secretion (Figure 3C). To further confirm that extracellularly secreted IL‐25 is responsible for cisplatin resistance in A549 cells, we treated A549 cells with exogenous IL‐25 and then tested the cells’ tolerance to cisplatin. First, A549 cells were subjected to different concentration of IL‐25 for 24 hours to detect the cytotoxicity of IL‐25 on cells. The results of flow cytometry analysis demonstrated that low concentration of exogenous IL‐25 (2 and 5 ng/mL) had no effect on A549 cells, even higher concentration of exogenous IL‐25 (10, 50, and 100 ng/mL) barely caused apoptosis (Figure S1B). Then, 5 ng/mL of exogenous IL‐25 was used to pretreat A549 cells for 24 hours, and the cisplatin‐resistant abilities of pretreated cells were measured. Our results showed that, compared with untreated A549 cells, A549 cells treated with IL‐25 had greater resistant capabilities (Figure 3D). Moreover, we found that whether treated with IL‐25 in advance or not the exogenous IL‐25 could significantly reduce the sensitivity of A549 cells to cisplatin (Figure 3E). Together, these data suggested that extracellular secreted IL‐25 promotes the formation of cisplatin resistance in lung cancer cells.

Figure 3.

Figure 3

Open in a new tab

Extracellular IL‐25 affects the cisplatin resistance of lung cancer cells. ELISA assay the expression of IL‐25 in the supernatant of A549 and A549/CDDP cells (A), in the supernatant of IL‐25 overexpressed A549 cells (B) and IL‐25 silenced A549/CDDP cells (C). D, Exogenous IL‐25 desensitizes A549 cells to cisplatin treatment. E, Apoptosis assay the effect of exogenous IL‐25 on the sensitivity of A549 cells to cisplatin. *P < 0.01 vs indicated controls, all figures represent the average of three sets of independent experiments

3.4. Major vault protein is the key factor for IL‐25 mediated cisplatin resistance of lung cancer cells

To further illustrate how IL‐25 regulates cisplatin resistance of lung cancer cells, we examined the expression of MVP, which is a well‐known multidrug‐resistant protein, in cisplatin‐resistant A549/CDDP cells. We found that, comparing with in A549 cells, the protein level of MVP was significantly elevated in A549/CDDP cells (Figure 4A). Additionally, we examined the effect of altering IL‐25 expression on the expression of MVP. Our data showed that overexpression of IL‐25 increased the MVP expression in A549 cells (Figure 4B), while knockdown of IL‐25 decreased the MVP expression in A549/CDDP cells (Figure 4C). Moreover, the exogenous IL‐25 also significantly induced the expression of MVP in A549 cells (Figure 4D). Interestingly, we also observed an IL‐25 concentration‐dependent increase of Bcl‐2 which is a well‐known anti‐apoptosis marker, while the apoptosis executive factor cleaved caspase3 has no significant change (Figure S2A). These data indicated that IL‐25 might enhance cisplatin resistance in lung cancer cells at least partly by increasing the expression of MVP and by enhancing its antiapoptotic ability.

Figure 4.

Figure 4

Open in a new tab

IL‐25 regulates the expression of major vault protein (MVP). A, The expression of MVP in A549 and A549/CDDP cells, in IL‐25 overexpressed A549 cells (B) and in IL‐25 silenced A549/CDDP cells (C). D, The effect of exogenous IL‐25 on the expression of MVP in A549 cells. *P < 0.01 vs indicated controls, all figures represent the average of three sets of independent experiments

3.5. IL‐25‐induced MVP elevation in lung cancer cells requires NF‐κB activity

IL‐25 is an NF‐κB signaling pathway activator participating in multiple physiological processes of tumor cell, such as proliferation, apoptosis, and metastasis.32, 33 Therefore, we supposed that IL‐25 mediates MVP expression by activating NF‐κB signaling pathway. To confirm our hypothesis, we detected the expression of NF‐κB signaling pathway‐associated proteins by western blot in IL‐25 overexpressed and silenced cells. Our data showed that overexpression of IL‐25 increased the phosphorylation of NF‐κB P65 and IκBα in A549 cells, while knockdown of IL‐25 decreased the phosphorylation of NF‐κB P65 and IκBα in A549/CDDP cells (Figure 5A). Meanwhile, our data also showed that exogenous IL‐25 increased the phosphorylation of NF‐κB P65 and IκBα in a concentration‐dependent manner (Figure 5B). To further illustrate that the NF‐κB activity is involved in IL‐25 mediated the regulation of MVP expression, we used QNZ (a NF‐κB inhibitor, 11 nmoL/mL) simultaneously with IL‐25 treating A549 cells, and the related proteins were detected by western blot at 24 hours after the treatment. Our data demonstrated, comparing with each DMSO control group, QNZ did not affect the expression of IL‐25 but inhibit the IL‐25‐induced phosphorylation of NF‐κB P65 and IκBα as well as the expression of MVP (Figure 5C). These data indicated that the IL‐25‐induced expression of MVP is dependent on the activation of NF‐κB signaling pathway.

Figure 5.

Figure 5

Open in a new tab

IL‐25 regulates the NF‐κB signaling pathway activity. A, The change of NF‐κB signaling pathway in IL‐25 overexpressed A549 cells and IL‐25 silenced A549/CDDP cells. B, The effect of exogenous IL‐25 on the activity of NF‐κB signaling pathway in A549 cells. C, QNZ blocks the effect of exogenous IL‐25 on the expression of major vault protein (MVP) and the activity of NF‐κB signaling pathway in A549 cells. *P < 0.01 vs indicated controls, all figures represent the average of three sets of independent experiments

3.6. Exogenous IL‐25 enhances cisplatin tolerance of lung cancer tumors, in vivo

The role of IL‐25 in cisplatin tolerance of lung cancer cells was also investigated in animal model. After a 2‐week treatment, the tumor sizes of cisplatin (5 mg/kg) alone treated nude mice (n = 8) were smaller than that in cisplatin along with IL‐25 (5 ng/mL) treated nude mice (Figure 6A). The average reduced rates of tumor volume were significantly lower in IL‐25 and cisplatin treated group than that in cisplatin treated control group (Figure 6B). Immunohistochemical staining analysis revealed extensive expression of MVP in the tumor tissues from IL‐25 and cisplatin treated group, whereas MVP expression was barely detected in the tumor tissues from only cisplatin treated group; meanwhile, the number of inflammatory cells were significantly reduced in the cisplatin and IL‐25 treated tumors (Figure 6C). The IL‐25 induced cisplatin tolerance was also verified by the elevated expression of Bcl‐2 and the reduced expression of cleaved caspase3 (Figure S2B). These data suggested that the existence of extracellular IL‐25 enhanced the cisplatin resistance of A549.

Figure 6.

Figure 6

Open in a new tab

The effect of IL‐25 in vivo experiment. A, The tumor sizes of cisplatin alone treated nude mice and cisplatin along with IL‐25 treated nude mice (n = 8). B, The average reduced rates of tumor volume in indicated groups. C, Representative microphotographs showing immunohistochemical staining analysis the expression of major vault protein (MVP) (magnification, ×100)

4. DISCUSSION

Acquired drug resistance in lung cancer cells is the main reason for the failure of chemotherapy treatment. There are many reasons for the drug resistance of lung cancer cells, but the molecular mechanism is not fully explained yet. In this study, we constructed a drug‐resistant lung adenocarcinoma cell line A549/CDDP. Consistent with our previously report, the IC50 of A549/CDDP cells was significantly enhanced.34 Interestingly, we found that the IC50 of parental A549 cells which we used in this study was significantly higher than that reported in our previous study, while the IC50 of A549/CDDP cell lines was lower than that reported in previously study.34 We suspect that it may be the parental A549 cells accumulating resistance‐related mutations during continuous passage, such as ROS mutations, resulting in differences in drug sensitivity of the same cell line. The genome‐wide sequencing analysis of two parental A549 cells is currently underway.

IL‐25 may play different roles in different cancers, either as a cancer suppressor or as a cancer promoter. In this study, we found that IL‐25 is highly expressed in cisplatin‐resistant cells. Manipulating the expression of IL‐25 in A549 cells or A549/CDDP cells changed their resistance to cisplatin accordingly. In addition, we also noticed that A549/CDDP cells increased the amount of extracellular IL‐25, and A549 cells treated with exogenous IL‐25 also enhanced its tolerance to cisplatin. It was also reported that, in the early stage, IL‐25 had a killing effect on lung cancer cells.13 However, even when treating the A549 cells with a high concentration of IL‐25 (600 ng/mL), no obvious apoptosis was observed (data not shown). Conversely, by treatment with IL‐25 (5 ng/mL), A549 cells had significantly higher tumorigenic capacity in vivo than the nontreated A549 cells (data not shown). Our data suggest that IL‐25 plays critical roles in promoting drug‐resistance of lung cancer cells.

Further study revealed that IL‐25 regulates cisplatin resistance of lung cancer cells by mediating the expression of MVP. Either intracellular overexpression of IL‐25 or exogenously treated with IL‐25 in A549 cells could increase the expression of MVP and enhance the tolerance to cisplatin. However, the molecular mechanism is not explained clearly. Previous studies have reported that IL‐25 activates the NF‐κB pathway to mediate inflammatory response,35, 36 and the activated NF‐κB could inhibit the occurrence of apoptosis.37, 38, 39 Therefore, next we explored whether NF‐κB signaling pathway is involved in the regulation of MVP expression. We found that IL‐25, especially extracellular IL‐25, could regulate the activity of NF‐κB signaling pathway and affect the expression of MVP. Moreover, we also found the expression of Bcl‐2 in exogenous IL‐25 treated A549 cells increased in a concentration‐dependent manner. In IL‐25 treated In vivo experiments group, we detected the elevated expression of Bcl‐2. Together, these findings suggest, in addition to inducting anti‐apoptosis, IL‐25 promotes cisplatin resistance of lung cancer cells partly by activating NF‐κB signaling pathway to increase the expression of MVP.

In conclusion, our findings revealed a novel mechanism of IL‐25‐ NF‐κB‐MVP cascade regulated formation of drug resistance. By targeting IL‐25 or its receptor may provide a potential therapy strategy for reversing cisplatin resistance of human lung adenocarcinoma.

CONFLICT OF INTEREST

The authors of this article declared they have no conflicts of interest.

Supporting information

 

Click here for additional data file. (229.3KB, pdf)

ACKNOWLEDGEMENTS

This work was supported by funds from National Natural Sciences Foundation of China (No. 81702921 and No. 81272597). Thanks for the experimental platform provided by the Institute of Burn Research, South West Hospital, AMU (TMMU).

Shen W, Qiu Y, Li J, et al. IL‐25 promotes cisplatin resistance of lung cancer cells by activating NF‐κB signaling pathway to increase of major vault protein. Cancer Med. 2019;8:3491–3501. 10.1002/cam4.2213

Weiming Shen and Yang Qiu contributed equally to this study.

Contributor Information

Yi Liao, Email: science0528@163.com.

Haidong Wang, Email: haidongwang1970@163.com.

REFERENCES

  • 1. Jemal A, Ward EM, Johnson CJ, et al. Annual report to the nation on the status of cancer, 1975–2014, featuring survival. J Natl Cancer Inst. 2017;109(9). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet‐Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87‐108. [DOI] [PubMed] [Google Scholar]
  • 3. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell. 2006;127(4):679‐695. [DOI] [PubMed] [Google Scholar]
  • 4. Goldman B. Multidrug resistance: can new drugs help chemotherapy score against cancer? J Natl Cancer Inst. 2003;95(4):255‐257. [DOI] [PubMed] [Google Scholar]
  • 5. Gao D, Vahdat LT, Wong S, Chang JC, Mittal V. Microenvironmental regulation of epithelial‐mesenchymal transitions in cancer. Cancer Res. 2012;72(19):4883‐4889. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Sato M, Shames DS, Gazdar AF, Minna JD. A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol. 2007;2(4):327‐343. [DOI] [PubMed] [Google Scholar]
  • 7. Aggarwal S, Gurney AL. IL‐17: prototype member of an emerging cytokine family. J Leukoc Biol. 2002;71(1):1‐8. [PubMed] [Google Scholar]
  • 8. Hurst SD, Muchamuel T, Gorman DM, et al. New IL‐17 family members promote Th1 or Th2 responses in the lung: in vivo function of the novel cytokine IL‐25. J Immunol. 2002;169(1):443‐453. [DOI] [PubMed] [Google Scholar]
  • 9. Dong C. Regulation and pro‐inflammatory function of interleukin‐17 family cytokines. Immunol Rev. 2008;226:80‐86. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Gaffen SL. Structure and signalling in the IL‐17 receptor family. Nat Rev Immunol. 2009;9(8):556‐567. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Barlow JL, McKenzie AN. IL‐25: a key requirement for the regulation of type‐2 immunity. BioFactors. 2009;35(2):178‐182. [DOI] [PubMed] [Google Scholar]
  • 12. Furuta S, Jeng YM, Zhou L, et al. IL‐25 causes apoptosis of IL‐25R‐expressing breast cancer cells without toxicity to nonmalignant cells. Sci Transl Med. 2011;3(78):78ra31. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Benatar T, Cao MY, Lee Y, et al. IL‐17E, a proinflammatory cytokine, has antitumor efficacy against several tumor types in vivo. Cancer Immunol Immunother. 2010;59(6):805‐817. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Benatar T, Cao MY, Lee Y, et al. Virulizin induces production of IL‐17E to enhance antitumor activity by recruitment of eosinophils into tumors. Cancer Immunol Immunother. 2008;57(12):1757‐1769. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Huang CK, Yang CY, Jeng YM, et al. Autocrine/paracrine mechanism of interleukin‐17B receptor promotes breast tumorigenesis through NF‐kappaB‐mediated antiapoptotic pathway. Oncogene. 2014;33(23):2968‐2977. [DOI] [PubMed] [Google Scholar]
  • 16. Wu HH, Hwang‐Verslues WW, Lee WH, et al. Targeting IL‐17B‐IL‐17RB signaling with an anti‐IL‐17RB antibody blocks pancreatic cancer metastasis by silencing multiple chemokines. J Exp Med. 2015;212(3):333‐349. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Izquierdo MA, Scheffer GL, Flens MJ, et al. Broad distribution of the multidrug resistance‐related vault lung resistance protein in normal human tissues and tumors. Am J Pathol. 1996;148(3):877‐887. [PMC free article] [PubMed] [Google Scholar]
  • 18. Scheffer GL, Wijngaard PL, Flens MJ, et al. The drug resistance‐related protein LRP is the human major vault protein. Nat Med. 1995;1(6):578‐582. [DOI] [PubMed] [Google Scholar]
  • 19. Kedersha NL, Miquel MC, Bittner D, Rome LH. Vaults. II. Ribonucleoprotein structures are highly conserved among higher and lower eukaryotes. J Cell Biol. 1990;110(4):895‐901. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Chugani DC, Rome LH, Kedersha NL. Evidence that vault ribonucleoprotein particles localize to the nuclear pore complex. J Cell Sci. 1993;106(Pt 1):23‐29. [DOI] [PubMed] [Google Scholar]
  • 21. Hamill DR, Suprenant KA. Characterization of the sea urchin major vault protein: a possible role for vault ribonucleoprotein particles in nucleocytoplasmic transport. Dev Biol. 1997;190(1):117‐128. [DOI] [PubMed] [Google Scholar]
  • 22. Abbondanza C, Rossi V, Roscigno A, et al. Interaction of vault particles with estrogen receptor in the MCF‐7 breast cancer cell. J Cell Biol. 1998;141(6):1301‐1310. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Herrmann C, Golkaramnay E, Inman E, Rome L, Volknandt W. Recombinant major vault protein is targeted to neuritic tips of PC12 cells. J Cell Biol. 1999;144(6):1163‐1172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Suprenant KA. Vault ribonucleoprotein particles: sarcophagi, gondolas, or safety deposit boxes? Biochemistry. 2002;41(49):14447‐14454. [DOI] [PubMed] [Google Scholar]
  • 25. Mossink MH, van Zon A, Scheper RJ, Sonneveld P, Wiemer EA. Vaults: a ribonucleoprotein particle involved in drug resistance? Oncogene. 2003;22(47):7458‐7467. [DOI] [PubMed] [Google Scholar]
  • 26. Scheper RJ, Broxterman HJ, Scheffer GL, et al. Overexpression of a M(r) 110,000 vesicular protein in non‐P‐glycoprotein‐mediated multidrug resistance. Cancer Res. 1993;53(7):1475‐1479. [PubMed] [Google Scholar]
  • 27. Kickhoefer VA, Rajavel KS, Scheffer GL, Dalton WS, Scheper RJ, Rome LH. Vaults are up‐regulated in multidrug‐resistant cancer cell lines. J Biol Chem. 1998;273(15):8971‐8974. [DOI] [PubMed] [Google Scholar]
  • 28. Siva AC, Raval‐Fernandes S, Stephen AG, et al. Up‐regulation of vaults may be necessary but not sufficient for multidrug resistance. Int J Cancer. 2001;92(2):195‐202. [DOI] [PubMed] [Google Scholar]
  • 29. Izquierdo MA, van der Zee AG, Vermorken JB, et al. Drug resistance‐associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst. 1995;87(16):1230‐1237. [DOI] [PubMed] [Google Scholar]
  • 30. Raaijmakers HG, Izquierdo MA, Lokhorst HM, et al. Lung‐resistance‐related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma. Blood. 1998;91(3):1029‐1036. [PubMed] [Google Scholar]
  • 31. List AF, Spier CS, Grogan TM, et al. Overexpression of the major vault transporter protein lung‐resistance protein predicts treatment outcome in acute myeloid leukemia. Blood. 1996;87(6):2464‐2469. [PubMed] [Google Scholar]
  • 32. Lv Q, Wu K, Liu F, Wu W, Chen Y, Zhang W. Interleukin17A and heparanase promote angiogenesis and cell proliferation and invasion in cervical cancer. Int J Oncol. 2018;53(4):1809‐1817. [DOI] [PubMed] [Google Scholar]
  • 33. He J, Zhao J, Peng X, Shi X, Zong S, Zeng G. Molecular mechanism of MiR‐136‐5p targeting NF‐kappaB/A20 in the IL‐17‐mediated inflammatory response after spinal cord injury. Cell Physiol Biochem. 2017;44(3):1224‐1241. [DOI] [PubMed] [Google Scholar]
  • 34. Tan W, Liao Y, Qiu Y, et al. miRNA 146a promotes chemotherapy resistance in lung cancer cells by targeting DNA damage inducible transcript 3 (CHOP). Cancer Lett. 2018;428:55‐68. [DOI] [PubMed] [Google Scholar]
  • 35. Umetsu DT, McIntire JJ, Akbari O, Macaubas C, DeKruyff RH. Asthma: an epidemic of dysregulated immunity. Nat Immunol. 2002;3(8):715‐720. [DOI] [PubMed] [Google Scholar]
  • 36. Tamachi T, Maezawa Y, Ikeda K, et al. IL‐25 enhances allergic airway inflammation by amplifying a TH2 cell‐dependent pathway in mice. J Allergy Clin Immunol. 2006;118(3):606‐614. [DOI] [PubMed] [Google Scholar]
  • 37. Xiao L, Lan X, Shi X, et al. Cytoplasmic RAP1 mediates cisplatin resistance of non‐small cell lung cancer. Cell Death Dis. 2017;8(5):e2803. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. Dong C, Yang R, Li H, et al. Econazole nitrate inhibits PI3K activity and promotes apoptosis in lung cancer cells. Sci Rep. 2017;7(1):17987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Yu M, Qi B, Xiaoxiang W, Xu J, Liu X. Baicalein increases cisplatin sensitivity of A549 lung adenocarcinoma cells via PI3K/Akt/NF‐kappaB pathway. Biomed Pharmacother. 2017;90:677‐685. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

 

Click here for additional data file. (229.3KB, pdf)

Articles from Cancer Medicine are provided here courtesy of Wiley

RESOURCES